NCM·Healthcare·$170M·#97 / 520 in Healthcare

MDXH MDxHealth SA

63SOLID

CATEGORY BREAKDOWN

GROWTH45
QUALITY61
STABILITY62
VALUATION97
GOVERNANCE71

METRIC BREAKDOWN

Revenue Growth (YoY)

Year-over-year revenue growth rate

+28.3%
45

> 50% strong

Gross Margin

Revenue retained after direct costs

61.2%
87

> 50% strong

Cash Runway

Months of cash at current burn rate

30 months
93

> 24 months ideal

Debt / Equity

Total debt relative to shareholder equity

404.7%
0

< 25% strong

Price / Sales

Market cap relative to trailing revenue

1.6x
97

< 3x strong

Rule of 40

Growth rate plus operating margin

2
22

> 40 excellent

Insider Ownership

Percentage of shares held by insiders

11.6%
68

> 20% strong

Share Dilution (12M)

Share count increase over last 12 months

+3.8%
77

< 5% ideal

5 more metrics available

Unlock all 8 metrics, score history, watchlist, and side-by-side comparison.

Try Free for 30 Days

AI ANALYSIS REPORT

AI-GENERATED

BUSINESS SUMMARY

MDxHealth SA (MDXH) is a healthcare company trading on NCM with a market capitalization of $170M. The company currently carries a SOLID rating of 63/100, indicating above-average fundamental quality. The fundamental profile shows solid revenue growth in the 25-50% range at 28.3% year-over-year, paired with strong gross margins well above industry average at 61.2%. The balance sheet shows high leverage that significantly increases financial risk, and the company has adequate cash runway of about 2 years.

VERDICT

MDXH scores 63/100 — a solid fundamental profile with room for improvement in select areas. This report is based on the latest available financial data and is intended as a starting point for research, not a buy or sell recommendation.

MARKET OPPORTUNITY

In the healthcare sector, cash runway and pipeline progress are critical metrics. Revenue quality depends on whether income comes from product sales, partnerships, or milestones. MDxHealth SA operates with meaningful insider ownership of 11.6%, which provides a signal about management's confidence in the company's direction. At a market cap of $170M, the company is attractively valued at under 3x price-to-sales at 1.6x P/S, which appears modest relative to the 28.3% revenue growth rate. The combination of these factors positions MDXH as a potentially interesting opportunity for investors seeking fundamental quality in the small-cap space.

REVENUE QUALITY

Revenue growth stands at 28.3% year-over-year, which is above the typical small-cap growth rate. Gross margins of 61.2% are strong and suggest pricing power or an asset-light business model. The Rule of 40 score of 2 is well below the benchmark, indicating challenges in both growth and profitability. Cash runway of 30 months provides a comfortable buffer for executing on growth plans.

COMPETITIVE ADVANTAGE

Evaluating MDxHealth SA's competitive position requires looking beyond the numbers. Insider ownership at 11.6% is relatively low, which may indicate that management's interests are less aligned with shareholders. The high gross margins suggest some form of competitive moat — whether through proprietary technology, brand value, regulatory barriers, or network effects. Share count management has been reasonable. Investors should research the specific sources of competitive advantage — patents, customer switching costs, scale economies, or brand — that could protect margins over time.

GROWTH THESIS

MDXH presents a reasonable fundamental case at current levels. At 1.6x P/S with 28.3% revenue growth, the valuation appears reasonable relative to the growth profile. Key catalysts to watch include: revenue growth trajectory over the next 2-3 quarters, margin expansion or contraction, and any changes in insider buying or selling activity.

KEY RISKS

Execution risk is significant — many small-cap companies in this sector fail to transition from growth to profitability. The elevated debt-to-equity ratio of 405x increases financial risk and limits the company's flexibility to weather downturns or invest in growth. Small-cap stocks carry inherently higher risk than large-caps, including limited analyst coverage, lower institutional ownership, and higher sensitivity to market downturns. Always conduct thorough due diligence beyond quantitative metrics.

Full AI Report available

Unlock the complete analysis including market opportunity, revenue quality, competitive moat, growth thesis, and risk assessment.

Try Free for 30 Days

Report generated: Mar 26, 2026

SCORE HISTORY

Track how this score changes over time. Start your free trial to see the full score trend chart.

SCORE ALERT

Get notified when MDXH's score changes by 5+ points.

DATA INFO

Last updated: Mar 11, 2026

Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.